For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is expected at 16-24% growth. However, this forecast, 3% lower for revenue and ...

People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in the first head-to-head study of the blockbuster medications. Clinical ...

People prescribed GLP-1 agents liraglutide (Saxenda) or semaglutide for weight loss decreased their alcohol intake by almost ...

A pronouncement from President Trump about the category drove their share prices down, although not to bargain-basement ...

Reducing exposure to medicines is always a good thing if similar clinical outcomes can be achieved, and the study suggests it ...

Recent health briefs reveal significant developments in the pharmaceutical sector. Key highlights include Trump's order ...

GlobalData analysis predicts the global GLP-1RA market will reach $168bn by 2033, with Novo Nordisk and Eli Lilly to dominate ...

Even if the order takes effect, it will do nothing to address the root causes of the problem it purports to solve.

Digital programs incorporating behavioral therapy led to solid reductions in body weight, and did so at lower drug doses.

For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is ...

The Canadian Medical Association (CMA) congratulates Canada's Minister of Health Marjorie Michel and the entire new federal cabinet on their appointments today. The CMA is eager to collaborate with ...

It looks like you're using an old browser. To access all of the content on Yr, we recommend that you update your browser. It looks like JavaScript is disabled in your browser. To access all the ...